In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease

Hepatology

Volumn 44, Issue 1, 2006, Pages 27-33

  Wieckowska, Anna ^a   Zein, Nizar N ^a   Yerian, Lisa M ^a   Lopez, A Rocio ^a   McCullough, Arthur J ^a   Feldstein, Ariel E ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CASPASE 3; CYTOKERATIN 18;

ADULT; APOPTOSIS; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FATTY LIVER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LIVER BIOPSY; LIVER CELL; MALE; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

APOPTOSIS; BIOLOGICAL MARKERS; BIOPSY; DIAGNOSIS, DIFFERENTIAL; FATTY LIVER; FEMALE; HEPATOCYTES; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINS; MALE; MIDDLE AGED; PROGNOSIS; ROC CURVE; SEVERITY OF ILLNESS INDEX;

EID: 33745904468     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21223     Document Type: Article

References (23)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-1231.
2. Wieckowska A, Feldstein AE. Nonalcoholic fatty liver disease in the pediatric population: a review. Curr Opin Pediatr 2005;17:636-641.
3. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129:113-121.
4. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-1419.
5. Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart LJ, Lindor KD, et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003;125:437-443.
6. Feldstein AE, Werneburg NW, Canbay A, Guicciardi ME, Bronk SF, Rydzewski R, et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. HEPATOLOGY 2004;40:185-194.
7. Ramalho RM, Cortez-Pinto H, Castro RE, Sola S, Costa A, Moura MC, et al. Apoptosis and Bcl-2 expression in the livers of patients with steatohepatitis. Eur J Gastroenterol Hepatol 2006;18:21-29.
8. Ribeiro PS, Cortez-Pinto H, Sola S, Castro RE, Ramalho RM, Baptista A, et al. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol 2004;99:1708-1717.
9. Feldstein AE, Gores GJ. Apoptosis in alcoholic and nonalcoholic steatohepatitis. Front Biosci 2005;10:3093-3099.
10. Bantel H, Ruck P, Gregor M, Schulze-Osthoff K. Detection of elevated caspase activation and early apoptosis in liver diseases. Eur J Cell Biol 2001;80:230-239.
11. Bantel H, Lugering A, Heidemann J, Volkmann X, Poremba C, Strassburg CP, et al. Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury. HEPATOLOGY 2004;40:1078-1087.
12. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. HEPATOLOGY 2005;41:1313-21.
13. Gao D, Wei C, Chen L, Huang J, Yang S, Diehl AM. Oxidative DNA damage and DNA repair enzyme expression are inversely related in murine models of fatty liver disease. Am J Physiol Gastrointest Liver Physiol 2004; 287:G1070-G1077.
14. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. HEPATOLOGY 2004;40:1387-1395.
15. Dam-Larsen S, Franzmann M, Andersen IB, Christoffersen P, Jensen LB, Sorensen TI, et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 2004;53:750-755.
16. Charlton M, Kasparova P, Weston S, Lindor K, Maor-Kendler Y, Wiesner RH, et al. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver Transpl 2001;7:608-614.
17. Cuadrado A, Orive A, Garcia-Suarez C, Dominguez A, Fernandez-Escalante JC, Crespo J, et al. Non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma. Obes Surg 2005;15:442-446.
18. Ramesh S, Sanyal AJ. Evaluation and management of non-alcoholic steatohepatitis. J Hepatol 2005;42(Suppl):S2-S12.
19. Feldstein AE, Canbay A, Guicciardi ME, Higuchi H, Bronk SF, Gores GJ. Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. J Hepatol 2003;39:978-983.
20. Canbay A, Friedman S, Gores GJ. Apoptosis: the nexus of liver injury and fibrosis. HEPATOLOGY 2004;39:273-278.
21. Canbay A, Guicciardi ME, Higuchi H, Feldstein A, Bronk SF, Rydzewski R, et al. Cathepsin B inactivation attenuates hepatic injury and fibrosis during cholestasis. J Clin Invest 2003;112:152-159.
22. Canbay A, Taimr P, Torok N, Higuchi H, Friedman S, Gores GJ. Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest 2003;83:655-663.
23. Seidel N, Volkmann X, Langer F, Flemming P, Manns MP, Schulze-Osthoff K, et al. The extent of liver steatosis in chronic hepatitis C virus infection is mirrored by caspase activity in serum. HEPATOLOGY 2005;42:113-120.